My ePortfolio Register   

WIN Symposium 2017 /
Genomic-driven clinical studies in breast cancer

26th - 27th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 2584

Prof José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Prof Baselga speaks with ecancer at WIN 2017 about widening trial targets and patient participation for new therapies against breast cancer.

He introduces phase I studies of taselisib, now escalating to a phase III study (SANDPIPER) combining the PI3K inhibitor with fulvestrant, aiming to improve specificity and toxicity compared to previous studies.

Prof Baselga discusses Akt inhibitors as single agents and used alongside immunotherapies, and a network to streamline patient recruitment to relevant clinical trials.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence